A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line

A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) is a phase 2/3, randomised interventional study registered as NCT07739199 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 200 participants, started 2026-08 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1; PD-1/VEGF bispecific antibody; Paclitaxel; Carboplatin. Conditions listed: Squamous Non-small-cell Lung Cancer. Primary outcome: Phase II: Investigator-assessed Objective Response Rate (ORR); Phase II: Investigator-assessed Progression-free Survival (PFS); Phase III: BICR-assessed Progression-free Survival (PFS). Lung eligibility wording from the registry: "Patients with locally advanced or metastatic squamous non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.